FDA approves Travere Therapeutics' FILSPARI for FSGS

13 Mwezi wa nne, 2026

Imeripotiwa na AI

The U.S. Food and Drug Administration approved FILSPARI, developed by Travere Therapeutics, as the first medicine for focal segmental glomerulosclerosis (FSGS). Travere announced the approval on April 13, 2026. Company executives held a business update conference call that evening to discuss the milestone.

Travere Therapeutics announced the FDA's approval of FILSPARI for FSGS patients earlier on April 13, 2026. The drug marks the first approved treatment for this kidney condition, according to the company. A press release and presentation slides are available on Travere's corporate website. The conference call featured President and CEO Eric Dube leading the discussion, joined by Chief Medical Officer Jula Inrig and Chief Commercial Officer Peter Heerma for prepared remarks. Chief Research Officer William Rote and Chief Financial Officer Chris Cline participated in the question-and-answer session. Analysts from firms including Leerink Partners, JPMorgan Chase, Guggenheim Securities, Wedbush Securities, TD Cowen, Cantor Fitzgerald, Wells Fargo Securities, Jefferies, Citigroup, BofA Securities, and Stifel joined the call. Nivi Nehra, Vice President of Corporate Communications and Investor Relations, opened the proceedings.

Makala yanayohusiana

Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

8 Mwezi wa sita, 2026 Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

Syntara reports positive FDA feedback on amsulostat trial

Syntara Limited held a shareholder webinar on April 29 to discuss FDA feedback on its proposed Phase IIb trial for amsulostat in myelofibrosis, along with a capital raise and quarterly report. CEO Gary Phillips highlighted the agreed path forward with regulators. The company lodged its Appendix 4C quarterly with the ASX.

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

13 Mwezi wa tano, 2026 Imeripotiwa na AI

A Japanese health panel has approved national health insurance coverage for Sumitomo Pharma's Amchepry, an iPS cell-derived treatment for Parkinson’s disease. The move makes it the world's first commercialized medical product from iPS cells.

Afya

FDA approves Eli Lilly’s once-daily obesity pill Foundayo

Biashara

Medartis hosts investor event in Basel on hand products

Europe

SpectraCure launches rights issue to finance studies

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

Caribou Biosciences presents car-t updates at healthcare conference

16 Mwezi wa tano, 2026 Imeripotiwa na AI

Caribou Biosciences discussed progress on its off-the-shelf CAR-T therapies during a presentation at the Bank of America Global Healthcare Conference on May 13. Chief executive Rachel Haurwitz highlighted Phase I data for two programs that target lymphoma and multiple myeloma.

Jumapili, 14. Mwezi wa sita 2026, 20:53:38